- Home
- KRG vs NUVL Comparison
KRG vs NUVL Comparison
Compare KRG & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRG
- NUVL
- Stock Information
- Founded
- KRG 1971
- NUVL 2017
- Country
- KRG United States
- NUVL United States
- Employees
- KRG N/A
- NUVL N/A
- Industry
- KRG Real Estate Investment Trusts
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- KRG Real Estate
- NUVL Health Care
- Exchange
- KRG Nasdaq
- NUVL Nasdaq
- Market Cap
- KRG 4.8B
- NUVL 5.6B
- IPO Year
- KRG 2004
- NUVL 2021
- Fundamental
- Price
- KRG $22.44
- NUVL $69.85
- Analyst Decision
- KRG Buy
- NUVL Strong Buy
- Analyst Count
- KRG 7
- NUVL 8
- Target Price
- KRG $28.00
- NUVL $115.50
- AVG Volume (30 Days)
- KRG 2.3M
- NUVL 625.4K
- Earning Date
- KRG 04-29-2025
- NUVL 05-08-2025
- Dividend Yield
- KRG 4.80%
- NUVL N/A
- EPS Growth
- KRG N/A
- NUVL N/A
- EPS
- KRG 0.06
- NUVL N/A
- Revenue
- KRG $856,165,000.00
- NUVL N/A
- Revenue This Year
- KRG $2.23
- NUVL N/A
- Revenue Next Year
- KRG $4.06
- NUVL N/A
- P/E Ratio
- KRG $362.06
- NUVL N/A
- Revenue Growth
- KRG 3.94
- NUVL N/A
- 52 Week Low
- KRG $18.52
- NUVL $55.54
- 52 Week High
- KRG $28.24
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- KRG 58.67
- NUVL 46.22
- Support Level
- KRG $22.03
- NUVL $63.56
- Resistance Level
- KRG $22.54
- NUVL $78.97
- Average True Range (ATR)
- KRG 0.54
- NUVL 3.46
- MACD
- KRG 0.13
- NUVL -0.38
- Stochastic Oscillator
- KRG 65.94
- NUVL 40.84
About KRG Kite Realty Group Trust
Kite Realty Group Trust specializes in owning, operating, acquiring, developing, and redeveloping high-quality open-air shopping centers and mixed-use assets. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.